Eupraxia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPRX research report →
Range $11 – $25
Price Chart
About the company
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis.
- CEO
- James A. Helliwell
- IPO
- 2024
- Employees
- 49
- HQ
- Victoria, BC, CA
Get TickerSpark's AI analysis on EPRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $390.16M
- P/E
- -5.59
- PEG
- 0.39
- P/S
- 0.00
- P/B
- 3.27
- EV/EBITDA
- -4.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.02%
- ROIC
- -53.19%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-38,434,039
- Net Income
- $-38,576,143-51.3%
- EPS
- $-1.03-35.5%
- OCF Growth
- +3.2%
- FCF Growth
- +1.6%
- 52W High
- $9.32
- 52W Low
- $5.63
- 50D MA
- $7.46
- 200D MA
- $7.18
- Beta
- 1.50
- RSI (14)
- 35
- Avg Volume
- 741.93K
No earnings-call transcripts are available for EPRX yet.
- Free Float
- 81.4%
- Shares Outstanding
- 67.27M
- Float Shares
- 54.74M
of shares held by institutions
68 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Beutel, Goodman & Co Ltd. | 3.53M | ▼ 98.74K |
| Affinity Asset Advisors, LLC | 1.72M | ▲ 66.32K |
| Scotia Capital Inc. | 1.43M | ▲ 81.34K |
| Balyasny Asset Management L.P. | 1.35M | ▲ 15 |
| Vivo Capital, LLC | 1.35M | 0 |
| Pfm Health Sciences, LP | 1.21M | ▲ 669.79K |
| Great Point Partners LLC | 1.20M | 0 |
| Jupiter Topco LLC | 1.05M | ▲ 1.05M |
| Rubric Capital Management LP | 867.42K | ▲ 176.25K |
| Ikarian Capital, LLC | 809.74K | ▼ 405.00K |
| Woodline Partners LP | 746.86K | ▲ 306.31K |
| Point72 Asset Management, L.P. | 730.28K | ▼ 237.29K |
Our EPRX coverage
Recent articles, reports, and earnings notes.
No research on EPRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPRX report →Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
globenewswire.com · Nov 10
Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 10
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
globenewswire.com · Oct 22
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
globenewswire.com · Oct 15
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
globenewswire.com · Oct 9
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
globenewswire.com · Sep 30
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
globenewswire.com · Sep 8
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
globenewswire.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.